OpenMTB‑Audit is an open‑source benchmark that tests large language models on 500 synthetic non‑small cell lung cancer cases, covering five adversarial error categories and four safety labels: Supported, Partially Supported, Unsupported, and Insufficient Information. The study found that all eight tested LLMs over‑refused Partially Supported recommendations, collapsing labels to achieve high safety scores. A deterministic seven‑module framework, MTB‑AuditAgent, was introduced to reduce over‑refusal to 6.7% and reach 91.2% accuracy, while an oncologist annotation study highlighted disagreement around the boundary between information sufficiency and treatment optimization.
arXiv:2608.28592v1 Announce Type: new Abstract: Large language models (LLMs) achieve high scores on medical knowledge examinations, yet real-world oncology is not a knowledge test--it is a sequence o...
arXiv:2606. 14149v1 Announce Type: new Abstract: Large Language Models (LLMs) are increasingly deployed in healthcare settings, yet their tendency to hallucinate poses risks when clinical decisions are involved.
arXiv:2607. 08602v1 Announce Type: new Abstract: Hepatocellular carcinoma (HCC) is a common malignancy and a leading cause of cancer-related mortality.
arXiv:2608.22085v1 Announce Type: new Abstract: Synthetic clinical data generation with large language models addresses the scarcity that limits cancer staging research, but oncology hallucinations a...
Lung cancer tissue diagnostics is complex, as therapy decisions in precision oncology rely on the integration of histomorphological, immunohistochemical, and molecular features. Yet pathological asses...
arXiv:2607. 10275v1 Announce Type: new Abstract: Large language models achieve high scores on medical knowledge assessments, yet clinical reasoning requires actively deciding what to investigate under uncertainty.
LUCAID is an agentic multimodal AI system designed for precision lung cancer pathology, integrating nine modules that cover the entire routine workflow—from quality control and tumor detection to histological subtyping, microenvironment profiling, cellularity quantification, and biomarker scoring (PD‑L1, MET, TROP‑2). The system generates automated structured reports and allows interactive querying of module outputs. In prospective clinical validation, LUCAID achieved 93.0% concordance with an expert‑panel reference standard for clinically actionable decisions, outperforming five experienced thoracic pathologists who ranged from 68.3% to 81.1% concordance.
arXiv:2609.01202v1 Announce Type: cross Abstract: Clinical trials are essential for advancing cancer care and drug development, but many fail because of insufficient patient enrollment. While there i...
arXiv:2603. 14158v2 Announce Type: replace-cross Abstract: Large language models (LLMs) are entering clinical workflows, yet evaluations rarely assess how clinician reasoning shapes model behavior during clinical interactions.
arXiv:2609.38181v1 Announce Type: new Abstract: Survival analysis estimates time-to-event outcomes from patient covariates and is widely used for medical risk assessment. Patients seeking prognostic...
arXiv:2608.30912v1 Announce Type: new Abstract: Artificial intelligence (AI) and natural language processing (NLP) are increasingly used to extract, integrate, and interpret biomedical knowledge rele...
arXiv:2510. 17532v2 Announce Type: replace-cross Abstract: Predicting cancer treatment outcomes requires models that are both accurate and interpretable, particularly in the presence of heterogeneous clinical data.